Trader consensus on Polymarket reflects an 83% implied probability for "No" new WHO-designated COVID-19 variant of concern before 2027, driven by the absence of any variants meeting strict VOC criteria like increased transmissibility, severity, or significant vaccine escape. ECDC's March 27, 2026, assessment lists zero VOCs, with Omicron BA.2.86 as the lone VOI and recent arrival BA.3.2 ("Cicada")—spreading to 29 countries and 25+ U.S. states since late 2025—demoted to variant under monitoring after genomic surveillance showed no alarming impacts despite its spike mutations. High global immunity from repeated vaccinations and infections, stable case trends, and the virus's shift to milder endemic patterns justify this positioning, though ongoing wastewater and traveler monitoring could flag shifts ahead of May's vaccine composition review.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · ActualizadoSí
$231,738 Vol.
$231,738 Vol.
Sí
$231,738 Vol.
$231,738 Vol.
The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Mercado abierto: Dec 1, 2025, 4:49 PM ET
Resolver
0x65070BE91...The CDC's variant classification scheme can be found here: https://stacks.cdc.gov/view/cdc/107682.
The resolution source for this market will be official information from the CDC.
Resolver
0x65070BE91...Trader consensus on Polymarket reflects an 83% implied probability for "No" new WHO-designated COVID-19 variant of concern before 2027, driven by the absence of any variants meeting strict VOC criteria like increased transmissibility, severity, or significant vaccine escape. ECDC's March 27, 2026, assessment lists zero VOCs, with Omicron BA.2.86 as the lone VOI and recent arrival BA.3.2 ("Cicada")—spreading to 29 countries and 25+ U.S. states since late 2025—demoted to variant under monitoring after genomic surveillance showed no alarming impacts despite its spike mutations. High global immunity from repeated vaccinations and infections, stable case trends, and the virus's shift to milder endemic patterns justify this positioning, though ongoing wastewater and traveler monitoring could flag shifts ahead of May's vaccine composition review.
Resumen experimental generado por IA con datos de Polymarket. Esto no es asesoramiento de trading y no influye en cómo se resuelve este mercado. · Actualizado
Cuidado con los enlaces externos.
Cuidado con los enlaces externos.
Preguntas frecuentes